Literature DB >> 21835539

Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?

Eberhard Stoeckle1, Benjamin Boubli, Anne Floquet, Véronique Brouste, Marie Sire, Sabrina Croce, Laurence Thomas, Frédéric Guyon.   

Abstract

OBJECTIVES: Interval debulking surgery (IDS) following neo-adjuvant chemotherapy (NAC) is a treatment option in advanced ovarian cancer. It is recommended to perform IDS early, after 3 cycles of NAC, but late IDS (after 6 cycles) may yield better results. Delaying IDS, however, harbours the risk of loosing the opportunity for debulking surgery. STUDY
DESIGN: Retrospective comparison of two groups of patients with advanced ovarian carcinoma (stages IIC-IV) treated by platinum-based chemotherapy (CT) having undergone early IDS (after 3.6 cycles, group 1, n=33) or late IDS (after 6.3 cycles, group 2, n=104). Contemporary patients who had undergone standard treatment by primary debulking surgery (PDS)+CT (group 3, n=446) and those treated by CT alone (group 4, n=64 patients) served as internal controls.
RESULTS: Prognosis in IDS patients (groups 1+2) was comparable to that in PDS patients (group 3). Only a few patients in group 4 potentially had lost an opportunity for debulking surgery. Groups 1 and 2 were well-matched concerning usual prognostic factors. Surgery extent and post-operative outcomes were similar in both. In contrast, complete cytoreductions were significantly more frequent in late than in early IDS (group 2 vs.1: 58% vs. 36%, p=0.03) and survival was not inferior in the late IDS group compared to the early IDS group with 37 vs. 22 months, respectively (p=0.09).
CONCLUSION: Late IDS yields higher complete resection rates than early IDS and should be evaluated prospectively for outcome in further trials.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835539     DOI: 10.1016/j.ejogrb.2011.07.014

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

1.  Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.

Authors:  Roni Nitecki; Nicole D Fleming; Bryan M Fellman; Larissa A Meyer; Anil K Sood; Karen H Lu; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2021-04-16       Impact factor: 5.304

Review 2.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

3.  Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?

Authors:  Yutaka Yoneoka; Mitsuya Ishikawa; Takashi Uehara; Hanako Shimizu; Masaya Uno; Takashi Murakami; Tomoyasu Kato
Journal:  J Gynecol Oncol       Date:  2019-09       Impact factor: 4.401

4.  Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer.

Authors:  Martina Aida Angeles; Bastien Cabarrou; Antonio Gil-Moreno; Asunción Pérez-Benavente; Emanuela Spagnolo; Agnieszka Rychlik; Carlos Martínez-Gómez; Frédéric Guyon; Ignacio Zapardiel; Denis Querleu; Claire Illac; Federico Migliorelli; Sarah Bétrian; Gwénaël Ferron; Alicia Hernández; Alejandra Martinez
Journal:  J Gynecol Oncol       Date:  2021-08-13       Impact factor: 4.401

5.  Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.

Authors:  Kazuto Nakamura; Yoshikazu Kitahara; Toshio Nishimura; Soichi Yamashita; Keiko Kigure; Ikuro Ito; Tatsuya Kanuma
Journal:  World J Surg Oncol       Date:  2020-08-13       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.